include the following information: safety and reactogenicity of a vaccine containing a novel adjuvant, co-administration data with pentavalent DTwP/HepB/Hib and OPV, efficacy in multiple transmission settings, efficacy data over 30 months of follow-up, an 18 month booster dose and efficacy against ...
Also, medical and public health services need to adapt their responses to the needs of isolated, disadvantaged and difficult-to-reach population groups to reduce disease outbreaks which affect vulnerable populations disproportionally. Summary recommendations from the review are shown in Text Box 1. Box...